UPDATE: Goldman Sachs Reinstates Neutral on BioMed Realty as Acquisitions Broaden Their Portfolio
In a report published on Friday, Goldman Sachs analyst Matthew Rand reinstated a Neutral rating on BioMed Realty (NYSE: BMR) and maintained its $21 price target on the company.
In the report, Goldman Sachs commented that, "We have removed the Not Rated designation from BioMed Realty shares. We rate BMR as a Neutral, with a 12-month, $21 price target. We continue to think that BMR's most relevant comp is Alexandria Real Estate Equities (ARE), which we also rate Neutral. In addition, we think that Digital Realty Trust (DLR, Buy) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."
BioMed Realty closed on Thursday at $20.50
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.